Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Glycomimetics Inc (NQ: GLYC ) 0.1782 -0.0010 (-0.56%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 16, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Glycomimetics Inc < Previous 1 2 3 4 5 6 Next > GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan July 25, 2024 From GlycoMimetics, Inc. Via Business Wire 7 Sorry Biotech Stocks Set to Make Investors Sad July 22, 2024 Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell. Via InvestorPlace Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday June 26, 2024 It's time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning! Via InvestorPlace Why GlycoMimetics Stock is Trading Higher Monday June 25, 2024 On Tuesday, the chief medical officer Edwin Rock disclosed in a Form4 that he bought 305 thousand shares in the company. Via Benzinga Earnings Outlook For GlycoMimetics March 26, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday June 25, 2024 Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning! Via InvestorPlace $1M Bet On This Penny Stock? Check Out These 4 Stocks Under $2 Insiders Are Aggressively Buying June 21, 2024 Via Benzinga GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) June 04, 2024 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024 May 29, 2024 From GlycoMimetics, Inc. Via Business Wire GLYC Stock Earnings: GlycoMimetics Misses EPS for Q1 2024 May 09, 2024 GLYC stock results show that GlycoMimetics missed analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Dow Surges Over 100 Points; EyePoint Pharmaceuticals Shares Plunge May 06, 2024 Via Benzinga Topics Stocks Exposures US Equities Crude Oil Gains 1%; TreeHouse Foods Shares Fall After Q1 Results May 06, 2024 Via Benzinga Exposures Fossil Fuels 12 Health Care Stocks Moving In Monday's Intraday Session May 06, 2024 Via Benzinga Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views May 06, 2024 Via Benzinga Topics Earnings Exposures Financial GlycoMimetics' Uproleselan Flunks In Late Stage Leukemia Study, Shares Sink May 06, 2024 Get insights on GlycoMimetics Inc's Phase 3 study results for uproleselan in R/R AML patients. Explore survival rates, adverse events, and future analyses. Via Benzinga Why Is Acutus Medical (AFIB) Stock Down 41% Today? May 06, 2024 Acutus Medical stock is down on Monday after the company reported a delisting notice that will hit AFIB shares later this week. Via InvestorPlace Why Is GlycoMimetics (GLYC) Stock Down 77% Today? May 06, 2024 GlycoMimetics stock is falling on Monday with heavy trading of GLYC after posting lackluster results from a Phase 3 trial of uproleselan. Via InvestorPlace 12 Health Care Stocks Moving In Monday's Pre-Market Session May 06, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday May 06, 2024 It's time to dive into the biggest pre-market stock movers with all of the hottest news worth reading about on Monday morning! Via InvestorPlace GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) May 06, 2024 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024 April 25, 2024 From GlycoMimetics, Inc. Via Business Wire 12 Health Care Stocks Moving In Tuesday's After-Market Session April 02, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's After-Market Session March 27, 2024 Via Benzinga GLYC Stock Earnings: GlycoMimetics Beats EPS for Q4 2023 March 27, 2024 GLYC stock results show that GlycoMimetics beat analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 March 27, 2024 From GlycoMimetics, Inc. Via Business Wire Earnings Scheduled For March 27, 2024 March 27, 2024 Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million. Via Benzinga GlycoMimetics: A Potential Game Changer In Blood Cancers With Near-Term Catalysts March 21, 2024 Glycomimetics' Uproleselan is expected to read out data in relapsed/refractory and elderly newly diagnosed Acute Myeloid Leukemia (AML) after 6 years in pivotal studies. Via Talk Markets GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024 March 13, 2024 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference February 26, 2024 From GlycoMimetics, Inc. Via Business Wire GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) February 12, 2024 From GlycoMimetics, Inc. Via Business Wire < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.